Abstract 345P
Background
Pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare subtype of non-small cell lung cancer, endemic in southeast Asia. LELC has histologic resemblance to undifferentiated nasopharyngeal carcinoma, which is highly sensitive to gemcitabine-platinum chemotherapy. Evidence to support this treatment in LELC is however limited. This study aims to evaluate the efficacy of gemcitabine-cisplatin (GP) or gemcitabine-carboplatin (GC) in relapsed or metastatic pulmonary LELC.
Methods
Consecutive patients with relapsed or metastatic pulmonary LELC who received palliative systemic therapies in 2010 – 2019 in Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong were reviewed. Treatment response was assessed by clinical history, physical examination, and imaging. Progression-free survival (PFS) and overall survival (OS) were estimated by the Kaplan-Meier method. Clinical predictors were analyzed by log-rank test and the Cox proportional hazard model.
Results
76 eligible patients (40 male, 36 female) were included. 59 patients received first-line gemcitabine-platinum chemotherapy—21 with GP and 38 with GC; the rest received other platinum doublets (n = 9), capecitabine-based chemotherapy (n = 7), or immunotherapy (n = 1). The median age was 58.7 years old; none of the tumors harbored EGFR or ALK mutation. The median chemotherapy cycles given was 4 for both GP/GC (range 1 – 8) and non-GP/GC (range 1 – 11). With a median follow-up of 26.0 months, the median PFS and OS for patients who received GP/GC were 9.5 and 28.6 months respectively. GP/GC had a significantly higher objective response rate (ORR) (78.0% vs 41.2%, p = 0.004) than non-GP/GC. No significant differences in ORR, PFS and OS between GP and GC were observed. On multivariate analyses, use of GP/GC was a significant predictive factor for longer PFS (HR 0.45, 95% CI 0.24 – 0.85, p = 0.013); presence of liver and bone metastasis were significant negative predictors for PFS.
Conclusions
This study confirms gemcitabine-platinum’s role as first-line treatment for relapsed or metastatic pulmonary LELC. Further studies are warranted to shape the optimal treatment landscape for this rare disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
333P - Efficacy and safety of immune checkpoint inhibitors alone or combined with chemotherapy in pulmonary sarcomatoid carcinoma
Presenter: Hiroyasu Kaneda
Session: Poster viewing 05.
334P - Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Geographic region subgroups in EMPOWER-Lung 1
Presenter: Gwo Fuang Ho
Session: Poster viewing 05.
335P - Real-world data of first-line treatment with pembrolizumab for non-small cell lung cancer with high PD-L1 expression (HOT/NJLCG2001)
Presenter: Hiroshi Yokouchi
Session: Poster viewing 05.
336P - Spatial characterisation of immune microenvironment in malignant pleural mesothelioma
Presenter: Dmitrii Shek
Session: Poster viewing 05.
337P - Association of clinical and molecular factors with immune checkpoint inhibitors efficacy in advanced non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Feng Li
Session: Poster viewing 05.
338P - Anti PD1 is superior to anti PDL1 when combined with chemotherapy in first-line treatment for metastatic non-small cell lung cancer (mNSCLC): A network meta-analysis
Presenter: Joe Wei
Session: Poster viewing 05.
339P - Analysis of first- and second-line immunotherapy efficacy in metastatic non-small cell lung cancer with low PD-L1 expression
Presenter: Charlotte McKay
Session: Poster viewing 05.
341P - Cost-effectiveness analysis of first-line atezolizumab for patients with stage IV non-small cell lung cancer whose tumours have a high-programmed death ligand 1 expression in Thailand
Presenter: Kankamon Kittrongsiri
Session: Poster viewing 05.
342P - Prognostic implications of PD-L1 co-expression among Filipino EGFR MT mNSCLC
Presenter: Herdee Gloriane Luna
Session: Poster viewing 05.